Codetta

Codetta Bio develops a multi-omics analysis platform that enables simultaneous measurement of proteins, DNA, and RNA from a single sample in a harmonized workflow, delivering results in a 3-hour instrument run. The company's Concerto System combines the precision of digital PCR with the dynamic range of qPCR, built on microbead-based target capture and powered by a unique blend of digital PCR, real-time PCR, and immunoPCR to deliver high-sensitivity, high-throughput results with unmatched precision. The platform serves applications across vaccine development, neurologic diseases, cell and gene therapy, infectious disease, liquid biopsy, oncology, gene editing, and immunology. Codetta Bio also offers Sonata Services for customized proof-of-concept projects tailored to specific applications. The company is opening 50 exclusive pilot project slots for Concerto Pioneers to generate data with the Concerto System. By enabling truly harmonized multi-omics data from a single sample, Codetta Bio addresses the critical challenge of integrating protein, DNA, and RNA biomarker analysis that traditionally requires separate instruments, workflows, and sample inputs, reducing sample requirements, improving data correlation, and accelerating translational research and clinical development. Founded in 2021 and headquartered in Morrisville, United States, Codetta Bio has raised approximately $27.3 million at the Series A stage from investors including Anzu Partners, Genoa Ventures, VC23, and Bantam Group.

Life Sciences Tech > Research & Development > Drug Informatics > Clinical Data Analysis > Omics Analysis,

Genomics > Genome Informatics > Integrative Bioinformatics Platforms